Chemotherapy use and survival among young and middle-aged patients with colon cancer

JAMA Surgery

Volumn 152, Issue 5, 2017, Pages 452-459

  Manjelievskaia, Janna ^a   Brown, Derek ^a   McGlynn, Katherine A ^b   Anderson, William ^b   Shriver, Craig D ^a,c   Zhu, Kangmin ^a,c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COLON ADENOCARCINOMA; COLON CANCER; COMORBIDITY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PRIMARY TUMOR; PRIORITY JOURNAL; SYSTEMIC THERAPY; YOUNG ADULT; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADOLESCENT; AGE; COLONIC NEOPLASMS; HEALTH SERVICE; PATHOLOGY; SURVIVAL RATE;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MEDICAL OVERUSE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; YOUNG ADULT;

EID: 85019955116     PISSN: 21686254     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamasurg.2016.5050     Document Type: Article

References (39)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30.
2. Schoen RE, Pinsky PF, Weissfeld JL, et al; PLCO Project Team. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012;366(25):2345-2357.
3. American Cancer Society. American Cancer Society recommendations for colorectal cancer early detection. http://www.cancer.org/cancer/colonandrectumcancer/moreinformation/colonandrectumcancerearlydetection/colorectal-cancer-early-detection-acs-recommendations. Accessed April 14, 2016.
4. US Preventive Services Task Force. Colorectal cancer: screening. http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/colorectal-cancer-screening. Accessed April 15, 2016.
5. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM; American College of Gastroenterology. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected] [published correction appears in Am J Gastroenterol. 2009;104(6):1613]. Am J Gastroenterol. 2009;104(3):739-750.
6. Fu J, Yang J, Tan Y, et al. Young patients (< 35 years old) with colorectal cancer have worse outcomes duetomore advanced disease: a30-year retrospective review. Medicine (Baltimore). 2014; 93(23):e135.
7. Chan KK, Dassanayake B, Deen R, et al. Young patients with colorectal cancer have poor survival in the first twenty months after operation and predictable survival in the medium and long-term: analysis of survival and prognostic markers. World J Surg Oncol. 2010;8:82.
8. Wang MJ, Ping J, Li Y, et al. The prognostic factors and multiple biomarkers in young patients with colorectal cancer. Sci Rep. 2015;5:10645.
9. Wang L, Hollenbeak CS, Stewart DB. Node yield and node involvement inyoung colon cancer patients: is there a difference in cancer survival based on age? J Gastrointest Surg. 2010;14(9):1355-1361.
10. Hemminki K, Santi I, Weires M, Thomsen H, Sundquist J, Bermejo JL. Tumor location and patient characteristics of colon and rectal adenocarcinomas in relation to survival and TNM classes. BMC Cancer. 2010;10:688.
11. O'Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Do young colon cancer patients have worse outcomes? World J Surg. 2004;28(6):558-562.
12. Jiang Z, Wang X, Tan X, Fan Z. Effect of age on survival outcomein operated and non-operated patients with colon cancer: a population-based study. PLoS One. 2016;11(1):e0147383.
13. Kneuertz PJ, Chang GJ, Hu CY, et al. Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. JAMA Surg. 2015;150(5):402-409.
14. Dalerba P, Sahoo D, Paik S, et al. CDX2 as a prognostic biomarker in stage II and stage II colon cancer. N Engl J Med. 2016;374(3):211-222.
15. André T, Boni C, Mounedji-Boudiaf L, et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl JMed. 2004;350(23):2343-2351.
16. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352(5):476-487.
17. Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendationson adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16): 3408-3419.
18. Jonker DJ, Spithoff K, Maroun J; Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Adjuvant systemic chemotherapy for stage II and III colon cancer after complete resection: an updated practice guideline. Clin Oncol (R Coll Radiol). 2011;23(5):314-322.
19. Vargas GM, Sheffield KM, Parmar AD, et al. Trends in treatment and survival in older patients presenting with stage IV colorectal cancer. J Gastrointest Surg. 2014;18(2):369-377.
20. Kirkpatrick HM, Aitelli CL, Qin H, Becerra C, Lichliter WE, McCollum AD. Referral patterns and adjuvant chemotherapy use in patients with stage II colon cancer. Clin Colorectal Cancer. 2010;9(3): 150-156.
21. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol. 2004;22(16):3395-3407.
22. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22(10):1797-1806.
23. Weiss JM, Schumacher J, Allen GO, et al. Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-Medicare data. Ann Surg Oncol. 2014;21(6):1781-1791.
24. Berian JR, Benson AB III, Nelson H. Young age and aggressive treatment in colon cancer. JAMA. 2015;314(6):613-614.
25. VanEenwyk J, Campo JS, Ossiander EM. Socioeconomic and demographic disparities in treatment for carcinomas of the colon and rectum. Cancer. 2002;95(1):39-46.
26. McGory ML, Zingmond DS, Sekeris E, Bastani R, Ko CY. A patient's race/ethnicity does not explain the underuse of appropriate adjuvant therapy in colorectal cancer. Dis Colon Rectum. 2006;49(3): 319-329.
27. Defense Health Agency. The Evaluation of the TRICARE Program: Fiscal Year 2014 Report to Congress. http://www.health.mil/Reference-Center/Reports/2014/02/25/Evaluation-of-the-TRICARE-Program. Accessed April 10, 2016.
28. American Joint Committeeon Cancer. AJCC Cancer Staging Manual. 6th ed. https://cancerstaging.org/references-tools/deskreferences/Documents/AJCC6thEdCancerStagingManualPart1.pdf. Published 2002. Accessed April 1, 2016.
29. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
30. Andaya AA, Enewold L, Zahm SH, et al. Race and colon cancer survival in an equal-access health care system. Cancer Epidemiol Biomarkers Prev. 2013;22(6):1030-1036.
31. Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001;93 (11):850-857.
32. Hamaker ME, van Rixtel B, Thunnissen P, Oberndorff AH, Smakman N, Ten Bokkel Huinink D. Multidisciplinary decision-making on chemotherapy for colorectal cancer: an age-based comparison. J Geriatr Oncol. 2015;6(3):225-232.
33. Jorgensen ML, Young JM, Solomon MJ. Adjuvant chemotherapy for colorectal cancer: age differences in factors influencing patients' treatment decisions. Patient Prefer Adherence. 2013;7:827-834.
34. Lewis C, Xun P, He K. Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: a 24-month follow-up. Support Care Cancer. 2016;24(4):1463-1471.
35. Domati F, Luppi G, Reggiani-Bonetti L, et al. The perception of health-related quality of life in colon cancer patients during chemotherapy: differencesbetween men and women. Intern Emerg Med. 2015;10(4):423-429.
36. Wiela-Hojenska A, Kowalska T, Filipczyk-Cisarz E, Łapinski Ł, Nartowski K. Evaluation of the toxicity of anticancer chemotherapy in patients with colon cancer. Adv Clin Exp Med. 2015;24(1):103-111.
37. Arndt V, Merx H, Stegmaier C, Ziegler H, Brenner H. Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: a population-based study. J Clin Oncol. 2004;22(23):4829-4836.
38. Guren MG, Dueland S, Skovlund E, Fosså SD, Poulsen JP, Tveit KM. Quality of life during radiotherapy for rectal cancer. Eur J Cancer. 2003; 39(5):587-594.
39. Chu E, Shi N, Wei W, Bendell JC, Cartwright T. Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer. Oncology. 2009;77(3-4): 244-253.